# Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

> **NCT00044551** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 29 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Taxane (Cytotoxic, BAY59-8862)

## Key facts

- **NCT ID:** NCT00044551
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044551, "Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00044551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*